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Relevance of Toll-like receptor-4 polymorphisms in renal trans-
plantation.
Background. Polymorphisms in Toll-like receptor-4 (TLR4)
have been reported to be associated with a blunted immune
response to microbial pathogens, as well as a decreased risk of
atherosclerosis in the general population. We assessed the im-
pact of the two TLR4 variants on the risk of severe infection, the
incidence of acute rejection, and the occurrence of atheroscle-
rotic complications in renal transplant recipients (RTR).
Methods. TLR-4 polymorphisms were assessed in a cohort
of 238 RTR. Post-transplant atherosclerotic events, acute re-
jection, severe bacterial infection, cytomegalovirus (CMV) dis-
ease, and opportunistic infections were evaluated as outcomes.
Results. The patients were followed for a mean duration of
95 ± 29 months after transplant. TLR4 polymorphism was ob-
served in 27 (11.3%) RTR. Subjects with TLR4 polymorphisms
were less likely to experience post-transplant atherosclerotic
events (RR 0.44; 95% CI 0.21 to 0.93; P = 0.02) and acute re-
jection (RR 0.41; 95% CI 0.30 to 0.83; P = 0.01), but presented
severe bacterial infections (RR 1.33; 95% CI 1.12 to 1.67; P
= 0.01) and opportunistic infections (RR 3.03; 95% CI 1.72
to 8.29; P = 0.008) more frequently. TLR4 polymorphism was
marginally associated with CMV disease (RR 1.47; 95% CI 0.95
to 2.64; P = 0.08).
Conclusion. RTR with TLR4 polymorphism present a lower
risk of post-transplant atherosclerotic events and acute allo-
graft rejection, but experience severe infectious episodes more
frequently. This subset of RTR may benefit from a less potent
immunosuppression regimen, along with increased preventive
measures against infectious agents.
Toll-like receptors (TLR) are recently discovered
germline-encoded, transmembrane receptors critical for
the detection of microbial pathogens [1]. Currently,
10 mammalian TLR have been identified. Among them,
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TLR4 is well known as the lipopolysaccharide (LPS) re-
ceptor. However, not only LPS, but also other exogenous
and endogenous ligands may bind to TLR4 and activate
the innate immune response [1]. Recently, Arbour et al
[2] discovered two single nucleotide polymorphisms in
the TLR4 gene that result in amino acid substitutions in
the extracellular domain of the receptor, with functional
consequences. These variants, Asp299Gly and Thr399Ile,
lead to a blunted immunologic response to inhaled LPS
[2], and to lower levels of proinflammatory cytokines,
acute-phase reactants, and soluble adhesion molecules
[3].
Concordant with these experimental data, subjects
with the Asp299Gly TLR allele have an increased risk
of infections [3, 4, 5]. Recent studies also suggested that
carriers of these TLR4 polymorphisms had a decreased
risk of atherosclerosis [3, 6, 7]. Stable renal transplant
recipients (RTR) have disproportionately high rates of
arteriosclerotic outcomes [8]. Our group has emphasized
the importance of inflammation and immunologic pro-
cesses in the pathogenesis of atherosclerosis after renal
transplantation [9, 10].
To date, no study has evaluated the impact of TLR4
polymorphisms on outcomes after transplantation. For
that purpose, we assessed the occurrence of the two TLR4
allele variants in a cohort of RTR, and analyzed the re-
lations among these polymorphisms, the risk of severe
infections, the incidence of acute rejection, and the de-
velopment of atherosclerotic complications.
METHODS
Patient characteristics
Three hundred and two consecutive RTR were en-
rolled consecutively. The study population of RTR was
derived from a cohort previously included in a study
assessing the association between lymphopenia and
atherosclerotic outcomes after renal transplantation [10].
Of the 302 patients, DNA was available from 238 individ-
uals (79%). These patients were transplanted between
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Table 1. Baseline characteristics and main outcomes after
transplantation in patients evaluated for TLR4 polymorphism and
those not included in the study because of DNA unvailability
RTR RTR not
evaluated evaluated
for TLR4 for TLR4
polymorphism polymorphism
(N = 238) (N = 64) P
Age 45 ± 11 48 ± 14 0.09
Sex ratio 61% 58% 0.24







Return to dialysis 7% 9.5% 0.10
Death after transplantation 5% 10% 0.08
January 1990 and June 2001. Reasons for DNA unavail-
ability were death (10%), return in dialysis (9.5%), and
loss of follow-up (1.5%).
These 238 individuals did not differ significantly in any
baseline parameter from the 64 not evaluated patients,
but were marginally less prone to atherosclerotic events,
graft loss, and death after transplantation (Table 1).
Patients were classified according to both the type of in-
duction as well as the type of maintenance immunosup-
pressive treatment.
Immunosuppressive regimen included induction by ei-
ther polyclonal antithymocyte globulins or monoclonal
anti-CD25 antibodies, followed by a maintenance im-
munosuppressive regimen. Monoclonal anti-CD25 an-
tibodies were used only in recipients older than
60 years. In those who had received polyclonal antithy-
mocyte globulins, cyclosporine A (CsA) or tacrolimus
were introduced only when serum creatinine concentra-
tion had decreased to half of the pretransplant level,
but not later than day seven post-transplant. CsA or
tacrolimus were introduced just before transplantation
in patients who received anti-CD25 antibodies. Four
maintenance immunosuppressive therapies were used
during this period: CsA-azathioprine-prednisone, CsA-
mycophenolate mofetil (MMF)-prednisone, tacrolimus-
MMF-prednisone, and MMF-prednisone.
Dialysis mode (none, hemodialysis, or peritoneal dial-
ysis) and its duration prior to transplantation were
recorded. Age, gender, past history of cardiovascular dis-
ease, hypertension, or diabetes mellitus, prior renal trans-
plantation, cytomegalovirus (CMV) donor/recipient
status, human lymphocytic antigen (HLA) compatibility,
and panel-reactive antibodies (PRA) were also analyzed
as covariates.
A pretransplant history of atherosclerotic events (AE)
was defined by (1) coronary heart disease—myocardial
infarction; coronary revascularization, including coro-
nary artery bypass surgery or percutaneous translumi-
nal coronary angioplasty; typical history of angina with
abnormal coronarography or myocardial scintigraphy,
(2) stroke/cerebrovascular disease—both nonhemor-
rhagic and hemorrhagic strokes; carotid endarterectomy,
and (3) abominal aortic or lower extremity arterial
disease—abominal aortic repair; lower extremity ampu-
tation; intermittent claudication confirmed by Doppler
or arteriography findings.
Hypertension was considered present if the patient re-
ceived antihypertensive drugs before transplantation.
CMV serology [enzyme-linked immunosorbent assay
(ELISA)] was performed in all the patients. No patient
received anti-CMV prophylaxis until May 2000. After
May 2000, CMV prophylaxis with valacyclovir was used
in CMV-negative recipients of a CMV-positive donor for
a three-month period post-transplant.
DNA extraction, D299G, and T399I TLR4
polymorphism
Genomic DNA (gDNA) was extracted from white
blood cells using standard salting out procedure. Both
TLR4 allele-specific polymorphisms were then studied
using a polymerise chain reaction (PCR)-based genotyp-
ing assay [11]. Briefly, in this assay, primers were designed
to create a restriction enzyme recognition site only in
the mutant allele. Thus, after PCR amplification of the
polymorphism regions of interest (249 bp and 407 bp in
length, respectively, for D299G and T399I TLR4 poly-
morphisms), PCR products were overnight digested with
NcoI and HinfI enzymes (Promega, France), respectively,
for D299G and T399I polymorphisms. Digestion prod-
ucts were then separated by a 3% standard agarose gel
electrophoresis. Digested PCR products of homozygote
muted DNA were 218 and 375 bp in length, respectively,
for D299G and T399I polymorphisms. Both size of band
in length (digested and undigested) were present in het-
erozygote samples. Sequencing of undigested PCR prod-
ucts confirmed restriction fragment length polymorphism
(RFLP)-PCR electrophoresis profiles for representative
samples (Fig. 1). For each PCR, negative control (PCR
amplification without gDNA) and positive control [PCR
amplification of a pcDNA3.1 plasmid (Invitrogen, Carls-
bad, CA, USA) carrying a cDNA fragment with both
mutations, and kindly provided by Dr. E. Lorentz, Duke
University Medical Center, Durham, NC, USA] were in-
cluded. Researchers and laboratory personnel had no
access to identifiable information, and could identify sam-
ples by number only.
OUTCOMES
Post-transplant atherosclerotic events
Coronary heart disease (CHD): myocardial infarc-
tion documented by serial 12-lead electrocardiogram
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Fig. 1. Asp299Gly and Tyr399Ile TLR4 polymorphism analysis for three representative samples, wild type (WT), heterozygote (H/h), and homozy-
gote mute (H), respectively, for both mutations. (A) Agarose gel electrophoresis of RFLP-PCR after NcoI and HinfI overnight restriction digest,
respectively, for D299G and T399I polymorphisms. MW represents molecular weight markers where deep band is 600 bp in length. (B) Sequencing
analysis of undigested PCR products from the same three samples, confirming RFLP-PCR analysis. N in the sequence determining by the sequence
analysis software (Applied Biosystems), and arrows in H/h samples depict overlay of two different allele-specific nucleotides.
evidence or Q-wave infarction and appropriate my-
ocardial enzyme elevations; coronary revascularization
including coronary artery bypass surgery or percuta-
neous transluminal coronary angioplasty; typical history
of angina with abnormal coronarography; sudden death
when a history of CHD was present.
Stroke/cerebrovascular disease: nonhemorrhagic
strokes confirmed by neurologic examination findings
consistent with new onset focal neurologic deficits,
with or without computed tomography or magnetic
resonance imaging evidence of cerebral infarction;
symptomatic extracranial artery stenosis, resulting in
carotid endarteriectomy.
Abdominal aortic or lower extremity arterial disease:
abdominal aortic repair; lower extremity revasculariza-
tion via bypass surgery or angioplasty; lower extremity
amputation; new onset of intermittent claudication con-
firmed by Doppler or arteriography findings.
Acute rejection
Acute rejection was considered in the presence of
serum creatinine elevation. All episodes of treated acute
rejection and biopsy-proven acute rejection were consid-
ered separately. Acute rejection was defined according to
the Banff classification [12]. Systematic biopsies were not
performed at any time of the study period.
Severe bacterial infections
Diagnosis of severe bacterial infections required bac-
terial infection-related hospitalization.
CMV disease
Diagnosis of CMV disease required the presence of
viral replication and a treatment by ganciclovir.
Opportunistic infections
Occurrence of opportunistic infections (Pneumocystis
carinii, tuberculosis, Epstein-Barr virus, toxoplasmosis,
aspergillosis, zoster infection, legionella pneumophilia)
were recorded.
Two physicians independent of the study and without
knowledge of baseline characteristics were responsible
for outcomes ascertainment. This analysis was performed
without knowledge of baseline characteristics.
Statistical analysis
Arithmetic mean was calculated and expressed as ±
SD. Using log-rank tests on Kaplan-Meier nonparamet-
ric estimates of the survival without AE distribution,
variables with a P value lower than or equal to 0.20
were selected. The selected variables were included into
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Table 2. Prevalence of carriage of the different alleles
N Total = 238 %
Asp299Gly alone 4 1.68%
Thr399Ile alone 1 0.42%
Both Asp299Gly and Thr399Ile 22 9.24%
Total Asp299Gly 26 10.92%
Total Thr399Ile 23 9.66%
Wild genotype 211 88.66%
different Cox proportional hazards models (atheroscle-
rotic events, infections, acute rejection), and a backward
stepwise selection process was performed, this time with
an a = 0.05. Age (≤36; 37–47; ≥48) and dialysis duration
(≤13; 14–23; ≥24) were split into tertiles. Results are ex-
pressed as relative risk (RR) and 95% CI, with a P value
testing the null hypothesis: RR = 1. Therefore, when
P value is less than 0.05, RR is significantly different from
1, either greater than 1 (i.e., risk of CVE is increased) or
less than 1 (i.e., risk of CVE is decreased). Assumptions
of Cox models (log-linearity, proportionality of risk in
time) were met in this analysis.
RESULTS
The cohort of 238 patients was followed for a mean
duration of 95 ± 29 months post-transplant. Mean follow-
up was similar in patients with TLR4 polymorphisms and
those with the wild genotype (92 ± 45 vs. 96 ± 27; P =
0.29). There was no difference in the timing of transplants
between the wild-type group and those with the TLR4
polymorphisms.
Mean age was 44 ± 12 years, and 139 (64%) were men.
Diabetes and hypertension were present in 10 patients
(4.2%) and 156 (72%), respectively. Mean dialysis dura-
tion was 20 ± 17 months, respectively. One hundred and
ninety-one patients (88%) had a positive CMV serology.
TLR4 polymorphisms
Twenty-six patients (10.9%) were heterozygous for
the Asp299Gly TLR4 allele. In 21 of these subjects,
cosegregation with the Thr399Ile allele was observed,
whereas only four had an isolated Asp299Gly polymor-
phism, which is in agreement with the cosegregate nature
of the TLR4 mutations [3]. One patient has an iso-
lated Thr399Ile TLR4 polymorphism. Overall, 27 pa-
tients (11.3%) had either Asp299Gly allele or Thr399Ile
allele, or both (Table 2), while 211 patients (88.7%) had
no detectable TLR4 mutations. The observed allele fre-
quencies were in Hardy-Weinberg equilibrium.
Patients with the TLR4 polymorphism did not differ
from carriers of the wild-type TLR4 genotype for age,
gender, diabetes mellitus, cardiovascular disease, dura-
tion of dialysis, prior transplantation, and anti-HLA im-
munization (Table 3). Similarly, HLA donor/recipient
Table 3. Baseline characteristics of patients with the wild-type TLR4




(N = 211) (N = 27) P
Age 45 ± 12 45 ± 11 0.46
Sex ratio 62% 61% 0.58
Pre-transplant diabetes 5% 0 0.18
Past history of cardiovascular 4.6% 3.8% 0.45
disease
Dialysis duration 18 ± 16 20 ± 17 0.41
First transplantation 91% 95% 0.31
HLA compatibility 2.4 ± 1.2 2.3 ± 0.9 0.39
PRA 5.3% 6.3% 0.44
Donor age 40 ± 15 36 ± 14 0.11
Use of ATG 90% 95% 0.19
HLA compatibility and donor age did not differ between
both populations (Table 3).
Atherosclerotic events
Fifty-four AE (22.7%) occurred in 54 patients (cere-
brovascular disease, 8; coronary heart disease, 31; periph-
eral vascular disease, 15), with a frequency of 28 AE for
1000 patients/year. Atherosclerotic events were signifi-
cantly less frequent in patients with TLR-4 polymorphism
(7.4% vs. 24.6%; P =0.025). Age (P <0.001), male gender
(P = 0.01), diabetes mellitus (P = 0.008), a past history of
cardiovascular disease (P < 0.001), and dialysis duration
(P = 0.03) were also risk factors for AE. In a multivariate
analysis, older age (RR 2.01; 95% CI 1.47 to 4.77), a past
history of cardiovascular disease (RR 3.27; 95% CI 1.94
to 5.62), and diabetes mellitus (RR 1.88; 95% CI 1.21 to
2.45) independently predicted the risk of AE. Subjects
with TLR4 polymorphism were significantly less likely to
have AE after transplantation (RR 0.44; 95% CI 0.21 to
0.93; P = 0.02).
Acute rejection
Fifty-seven (23.9%) patients experienced at least one
episode of acute rejection. The presence of TLR4 poly-
morphism reduced the risk of acute rejection (7.4% vs.
26.1%; P = 0.02).
Patients with acute rejection were also younger (41 ±
12 vs. 46 ± 13 years; P = 0.01).
In multivariate analysis, both older age (RR 0.78; 95%
CI 0.67 to 0.96) and TLR4 polymorphism (RR 0.41; 95%




Fifty-nine (24.8%) patients experienced at least one
episode of severe acute bacterial infection. Severe acute
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Table 4. Post-transplant outcomes in patients with the wild-type




Acute rejection 26.1% 7.4% 0.02
Bacterial infections 21.3% 51.9% 0.002
CMV disease 23.2% 44.4% 0.02
Opportunistic infections 6.2% 22.2% 0.008
All infections 36.4% 85.2%
Atherosclerotic events 24.6% 7.4% 0.025
Return to dialysis 10.1% 11.1% 0.45
Death 5.7% 0 0.11
bacterial infections were more frequent in subjects with
TLR4 polymorphisms (51.9% vs. 21.3%; P = 0.002). In
multivariate analysis, recipient age (RR 3.11; 95% CI 1.87
to 6.12), use of polyclonal antithymocyte globulins (RR
2.07; 95% CI 1.21 to 5.45), and TLR4 polymorphism (RR
1.33; 95% CI 1.12 to 1.67; P = 0.03) increased the risk of
bacterial infections.
Opportunistic infections (other than CMV)
Nineteen (7.6%) patients experienced at least one op-
portunistic infection [zoster infections, 5; P. carinii, 7;
aspergillosis, 2; alternariosis, 1; toxoplasmosis, 2; Epstein-
Barr virus (EBV) infection, 1; legionellosis, 1]. Oppor-
tunistic infections were more frequent in subjects with
TLR4 polymorphisms (22.2% vs. 6.2%; P = 0.008). In
multivariate analysis, use of polyclonal antithymocyte
globulins (RR 2.24; 95% CI 1.41 to 4.27) and TLR4 poly-
morphism (RR 3.03; 95% CI 1.72 to 8.29; P = 0.01) in-
creased the risk of opportunistic infections.
Cytomegalovirus disease
Sixty-one (25.6%) patients experienced at least one
episode of CMV disease. CMV disease was more frequent
in subjects with TLR4 polymorphisms (44.4% vs. 23.2%;
P = 0.02).
In multivariate analysis, recipient age (RR 2.34; 95%
CI 1.39 to 5.63) and donor CMV seropositivity (RR 2.51;
95% CI 1.28 to 8.95) increased the risk of CMV dis-
ease, while TLR4 polymorphism was marginally associ-
ated with CMV disease (RR 1.47; 95% CI 0.95 to 2.64;
P = 0.08).
As a whole, serious infectious complications, including
severe bacterial infections, CMV disease, and opportunis-
tic infections were significantly more frequent in subjects
with TLR4 polymorphisms (85.2% vs. 36.4%; P < 0.001).
Relationships between TLR4 polymorphisms and
post-transplant outcomes are summarized in Table 5.
DISCUSSION
Human TLR-4 polymorphisms Asp299Gly and
Thr399Ile, which affect the extracellular domain of the
Table 5. Cox models: TLR polymorphisms and relative risks (RR) of
the different outcomes and 95% CI
RR CI 95% P
Atherosclerotic events 0.44 0.21–0.93 0.02
Bacterial infections 1.33 1.12–1.67 0.03
Opportunistic infections 3.03 1.72–8.29 0.01
CMV disease 1.47 0.95–2.64 0.08
Acute rejection 0.41 0.30–0.83 0.01
The results of the different Cox models are used in this table.
receptor, impair the capacity to elicit inflammation. Of
the 238 renal transplant patients tested, 27 (11.3%) were
heterozygous or homozygous for one and/or both TLR-4
polymorphisms. Such a frequency is within the range
of frequencies previously reported [13]. Also similar to
previous findings is the high frequency of cosegregation
(81%) of Asp299Gly and Thr399 Ile polymorphisms in
our patients. Such a cosegregation might be in relation
with the fact that the Thr399 Ile might partly restore the
TLR-4–mediated signaling interruption mediated by the
Asp299 Gly polymorphisms [2].
Toll-like receptors represent the main class of pattern-
recognition receptors involved in sensing pathogenic mi-
croorganisms. The common polymorphisms in TLR4 are
associated with hyporesponsiveness to inhaled endo-
toxin or LPS, and increase the risk and severity of both
Gram-negative bacterial [4, 5] and viral [14] infections.
Concordant with these data, our study shows an increased
incidence of severe bacterial infections, CMV disease,
and opportunistic infections in TLR4 polymorphism car-
riers, suggesting an attenuated innate immune defense
in these patients. TLR4 is directly involved in immune
responses against both Gram-negative and -positive bac-
teria. By contrast, TLR4 is not directly involved in CMV
recognition, but Lore et al [15] demonstrated that TLR
ligand-induced activation of dendritic cells greatly en-
hanced the ability of these cells to present CMV antigens,
resulting in increased frequencies of activated antigen-
specific CD4 and CD8 T cells. Therefore, patients with
decreased TLR4 function might have an impaired cellu-
lar response to CMV. These results highly suggest that
TLR4 function contributes to immune defense against
pathogens, even in immunocompromised patients.
Despite some controversies [16, 17], accumulating evi-
dence suggests a role for TLR4 pathway in atheroscle-
rosis. Kiechl et al [3] first reported that patients with
the Asp299Gly TLR4 allele had a lower risk of carotid
atherosclerosis defined according to ultrasonographic
criteria. The authors also observed a trend toward a
decreased incidence of cardiovascular disease in pa-
tients with TLR4 polymorphism. Nevertheless, the dif-
ference did not reach the statistical significance. More
recently, Boekholdt et al [7] reported that among symp-
tomatic men with documented coronary artery disease,
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the TLR4Asp299Gly polymorphism was associated with
the risk of cardiovascular events. Some other studies
reported similar results [8]. These clinical results are
supported by experimental evidence obtained in animal
models. Studies on different strains and inbred mice for
their susceptibility for atherosclerosis showed that there
are considerable differences between the strains. Indeed,
the natural TLR4-deficient C3H/HeJ strain (insensible
to LPS) is one of the strains that is less susceptible to
atherosclerosis [18]. Furthermore, reduced atheroscle-
rosis has been observed in MyD88 (the TLR universal
signal adaptor protein)-null mice through a decrease in
macrophage recruitment to the artery wall that has been
associated with reduced chemokine levels [19]. While
both of these findings suggest that TLR pathway is cru-
cial for atherogenesis, some other animal models fail to
confirm a role for TLR4 polymorphisms in atherosclero-
sis. For instance, Wright et al [20] reported no difference
in the extent of aortic atherosclerosis between standard
apolipoprotein-E–deficient mice and mice that were also
deficient in TLR4.
Our data suggest that TLR4 plays a pivotal role in
atherogenesis after renal transplantation. Our results
cannot be explained by a greater than expected inci-
dence of AE in the wild-type TLR4 genotype popula-
tion. Compared to previous studies in our center [9, 10,
21], the incidence of AE observed in this trial is low, and
the difference is so mainly due to a very low frequency
of atherosclerotic complications in TLR4 polymorphism
carriers. Considering that our study included patients
with a low-risk of atherosclerotic events, a greater bene-
fit of Asp299Gly polymorphism may be observed in the
whole RTR population.
In this study, we also observed that subjects with TLR4
polymorphisms were less likely to have acute rejection
than subjects with the wild-type TLR4, even after ad-
justment for confounding factors. The role of TLR4 sig-
naling in acute rejection is controversial. A recent study
found a decreased incidence of acute rejection in lung
transplant recipients with TLR4 polymorphisms [22]. In
hematopoietic stem cell transplantation recipients, the
presence of TLR4 mutations in recipient or donor has
been reported to be possibly associated with reduced risk
of acute graft-versus-host disease and an increased risk
of Gram-negative bacteremia without, however, reach-
ing statistical significance [23]. In a murine skin allograft
model, Goldstein et al [24] demonstrated that TLR4 −/−
recipients were able to reject allografts in a fashion similar
to that of littermate controls even when one TLR4 −/−
recipient manifested indefinite survival. More recently,
Samstein et al [24] reported similar results. Nevertheless,
in the study by Goldstein [24], allograft rejection could
not occur in the absence of MyD88, indicating that TLRs
may be activated by endogenous ligands and not solely
by pathogen-associated recognition patterns (PAMPs),
and that the TLR pathway was crucial for alloreactive
responses. In fact, TLRs can be activated by a variety of
ligands, including heat shock proteins, hyaluronan, and
fibronectin, all of them implicated in the pathogenesis
of acute allograft rejection, and induce the synthesis and
release of inflammatory cytokines and chemokines, and
costimulatory molecules [25, 26]. An alternative explana-
tion is that contaminating microorganisms of the allograft
stimulate TLRs using PAMPs. Indeed, there are several
reports that infectious agents, mainly viruses, can modify
acute rejection in experimental and clinical transplanta-
tion [27, 28]. LPS is also increased in reperfusion injury
and might contribute to TLR activation in allograft. Fi-
nally, TLR-4 may play a role in LPS-induced acute renal
failure, as demonstrated by Cunningham et al in animal
models [29]. Further studies should determine the precise
mechanisms linking TLR4 polymorphisms and alloreac-
tive responses.
While most previous studies have examined the con-
sequences of TLR4 polymorphisms in cohorts of healthy
men and women, we assessed the consequences of such
polymorphisms in a group of patients carrying a highly
specific immunologic context. Similarly, animal studies
mentioned previously were performed in the absence
of immunosuppressive drugs. Indeed, RTR have a num-
ber of characteristics that can all potentially impact on
the clinical consequences of differing TLR4 signaling.
Prior to transplantation, such recipients experienced ter-
minal renal insufficiency with a number of metabolic and
inflammatory disorders that could rely in part on TLR4-
signaling in APC to mediate their pathogenic effects. Sim-
ilarly and, as mentioned previously, transplantation per
se could potentially induce LPS-mediated TLR-4 signal-
ing. Pre- and especially post-transplant immunosuppre-
sion at a time of enhanced microbial- or allomediated
solicitation of immunity might also result in modulating
the consequences of TLR4 polymorphisms. Furthermore,
and in addition to the great number of TLR-4 ligands
possibly present in large amounts in transplant recipi-
ents, LPS or inflammatory cytokines such as IFN-gamma
can up-regulate TLR4 expression [30]. Lastly, by block-
ing IL-2 synthesis or IL-2–mediated signaling, drugs such
as cyclosporine may alter the multiple interactions (and
in particular the negative feedback) between acquired
immunity and innate immunity [1]—and consequently
enhance the overall potency of the innate immune re-
sponses. Therefore, in such a context of diminished
acquired immunity and increased “danger” signals, any
dysregulation in innate immunity may have dispropor-
tionate consequences, as suggested by our study.
A selection bias is likely in our study. All the results in-
dicate that we included low-risk patients regarding risks
of cardiovascular disease, graft failure, and death. More-
over, a survival bias could not be totally excluded. A
differential rate of graft and patient survival or DNA
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availability between patients with the wild type and those
with TLR4 mutations may also have influenced our re-
sults. Nevertheless, all these limitations should favor the
null hypothesis, and not contribute to a false-positive
result. Moreover, we observed that the prevalence and
impact of TLR4 polymorphism are similar in patients
with available pretransplant DNA and in those who
were investigated after transplantation (data not shown).
Because a bias of DNA conservation is unlikely, our
results are likely to be applicable to the whole trans-
plant population. We cannot exclude the possibility that
TLR4 variants serve as marker of another important
genetic abnormality without themselves being function-
ally relevant. The frequency of isolated Asp299Gly car-
riership was low in our cohort, which is consistent with
previous reports [3, 4]. Previous reports have suggested
that the genotype at residue 399 influences the effect of
the Asp299Gly polymorphism. 299Gly carriership in the
presence of 399Ile carriership predicts decreased TLR4
function, but 299Gly carriership in the absence of 399Ile
carriership yields a TLR4 protein which functions even
worse.
For a genetic test to be relevant in clinical manage-
ment, it is obviously critical that the test have additional
predictive power over and above the presently avail-
able and easily assessable risk factors. Our study does
not include all potential confounding variables; we find
that TLR4 genotype adds significantly to the power of
some of the strongest predictor of post-transplant car-
diovascular disease (CVD), such as diabetes mellitus
and pretransplant CVD. Similarly, the presence of TLR4
polymorphism decreased the risk of acute rejection while
increasing the risk of serious infections independently of
traditional risk factors for these outcomes. Because ap-
proximately 10% of RTR carry the Asp299Gly polymor-
phism, it is likely that the pretransplant determination
of TLR4 genotype might offer the opportunity to mod-
ulate the immunosuppressive treatment, and optimize
the monitoring and prophylaxis of post-transplant infec-
tions in a substantial proportion of the transplant popu-
lation. For instance, polyclonal antithymocyte globulins
should probably be avoided in Asp299Gly TLR4 poly-
morphism carriers, while primary prevention of CMV
and bacterial infections should be used systematically. We
suggest that TLR4 genotype should be performed prior
to transplantation to help physicians in determining the
risk profile of the recipient and accurate the treatment
strategy.
CONCLUSION
Overall, our study highly suggests that Asp299Gly
TLR4 polymorphism in RTR is associated with a lower
risk of acute rejection and a decreased rate of atheroscle-
rotic complications, as well as an enhanced risk of severe
bacterial infections. Such preliminary results should stim-
ulate prospective clinical trials in which the significance
of TLR4 polymorphisms, as well as other SNPs (e.g.,TNF
alpha), would be assessed to help physicians in deter-
mining recipient risk profile, and in optimizing pre- and
post-transplant treatment strategies.
Reprint requests to Dr. Didier Ducloux, Department of Nephrol-
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